A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)
Status:
Terminated
Trial end date:
2020-08-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose
(MTD) and/or recommended phase 2 dose (RP2D) of TAK-659 when administered in East Asian
participants with NHL who do not have an effective standard treatment available and to
characterize the plasma and urine pharmacokinetic (PK) of TAK-659 in East Asian participants
with NHL.